ERBB2 and neoplasm: Rosembaun et al., in 2020, studied a group of 7 patients with metastatic breast cancer negative to the expression of HER2 that were administered with a vaccine designed with the tumor-associated carbohydrate antigen (Tn), the toxin-derived peptide of tetanus TT830–844, and the immunostimulant GSK AS15.